![Jeffery Errington](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jeffery Errington
Fondatore presso Demuris Ltd.
Profilo
Jeffery Errington is the founder of Demuris Ltd.
(founded in 2007) and serves as the Chief Executive Officer & Director.
Dr. Errington is also the founder of Prolysis Ltd.
Dr. Errington's former job positions include being an Independent Non-Executive Director at Biota Holdings Pty Ltd.
(2010-2013), Director-Centre for Bacterial Cell Biology at The University of Newcastle (2012), Non-Executive Director at Aviragen Therapeutics, Inc. (2012-2013), and Professor-Microbiology at the University of Oxford.
Dr. Errington's education includes a graduate degree from the University of Oxford and an undergraduate degree from The University of Newcastle.
Posizioni attive di Jeffery Errington
Società | Posizione | Inizio |
---|---|---|
Demuris Ltd.
![]() Demuris Ltd. Medical DistributorsDistribution Services Demuris Ltd. develops portfolio of novel antibiotics. The firm is an antibiotic discovery company, which provides technologies of genome engineering, natural product sourcing, and target-based screening. It's products include broad spectrum, gram positive, tuberculosis, anti-fungal, and anti-cancer programs. The company was founded by Jeffery Errington on May 22, 2007 and is headquartered in Newcastle-upon-Tyne, the United Kingdom. | Fondatore | 22/05/2007 |
Precedenti posizioni note di Jeffery Errington
Società | Posizione | Fine |
---|---|---|
BIOTA HOLDINGS LTD. | Direttore/Membro del Consiglio | 12/08/2013 |
Aviragen Therapeutics, Inc.
![]() Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Direttore/Membro del Consiglio | 12/08/2013 |
The University of Newcastle | Corporate Officer/Principal | - |
University of Oxford | Corporate Officer/Principal | - |
Prolysis Ltd.
![]() Prolysis Ltd. Pharmaceuticals: MajorHealth Technology Prolysis Ltd. develops and manufactures pharmaceutical products. It develops antibacterial therapy to treat drug resistant infections. The company was founded in 1998 and is headquartered in Kidlington, UK. | Fondatore | - |
Formazione di Jeffery Errington
University of Oxford | Graduate Degree |
The University of Newcastle | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 4 |
---|---|
Prolysis Ltd.
![]() Prolysis Ltd. Pharmaceuticals: MajorHealth Technology Prolysis Ltd. develops and manufactures pharmaceutical products. It develops antibacterial therapy to treat drug resistant infections. The company was founded in 1998 and is headquartered in Kidlington, UK. | Health Technology |
Biota Holdings Pty Ltd.
![]() Biota Holdings Pty Ltd. Pharmaceuticals: MajorHealth Technology Biota Holdings Pty Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia. | Health Technology |
Demuris Ltd.
![]() Demuris Ltd. Medical DistributorsDistribution Services Demuris Ltd. develops portfolio of novel antibiotics. The firm is an antibiotic discovery company, which provides technologies of genome engineering, natural product sourcing, and target-based screening. It's products include broad spectrum, gram positive, tuberculosis, anti-fungal, and anti-cancer programs. The company was founded by Jeffery Errington on May 22, 2007 and is headquartered in Newcastle-upon-Tyne, the United Kingdom. | Distribution Services |
Aviragen Therapeutics, Inc.
![]() Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Health Technology |
- Borsa valori
- Insiders
- Jeffery Errington